Zynex Inc CEO Thomas Sandgaard joined Steve Darling from Proactive to detail the impressive growth and cutting-edge innovations that have defined the company’s 28-year journey. Since its founding, Zynex has expanded to generate nearly $200 million in revenue while maintaining strong profitability. Sandgaard outlined the company’s two main business divisions: pain management and hospital monitoring. Zynex has made significant advances in hospital monitoring, particularly with the development of four innovative products, including one that targets the pulse oximetry market and is expected to receive FDA approval in the near future. This device will also accurately detect carbon monoxide levels, as well as reductions in hemoglobin and myoglobin, offering improved patient diagnostics. In the pain management division, Zynex has already assisted over one million patients by offering devices that reduce reliance on opioids and enhance recovery times. Looking ahead, the company aims to grow its pain management revenue to $800 million while continuing to advance its hospital monitoring technology. #proactiveinvestors #zynexinc #nasdaq #zyxi #healthcare #q2 #finanacials #MedicalDevices #HealthcareInnovation #PainManagement #HospitalMonitoring #ThomasSandgaard #FDAApproval #RevenueGrowth #Proactive #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews